Analyst Reco. Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 18/02/2026 GMT			5-day change	1st Jan Change
99.79 ^USD	-0.82%		+1.84%	+25.29%

02-11	Revolution Medicines, Inc. Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026, Feb-11-2026 09:30 AM
01-29	Revolution Medicines Says First Patient Dosed in Solid Tumor Trial	MT

Analyst Reco.

01-21	RBC Boosts Price Target on Revolution Medicines to $140 From $77, Keeps Outperform, Speculative Risk	MT
01-13	Mizuho Adjusts Price Target on Revolution Medicines to $143 From $90, Maintains Outperform Rating	MT
01-09	Wedbush Raises Price Target on Revolution Medicines to $147 From $80, Keeps Outperform Rating	MT
01-06	Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says	MT
01-06	BofA Adjusts Price Target on Revolution Medicines to $98 From $82, Maintains Buy Rating	MT
11-06	Wedbush Lifts Price Target on Revolution Medicines to $80 From $77, Keeps Outperform Rating	MT
11-03	Revolution Medicines is Best-Positioned to Execute Targeting RAS-Mutated Cancers, RBC Says	MT
11-03	RBC Initiates Revolution Medicines at Outperform, Speculative Risk With $77 Price Target	MT
21/10/25	Mizuho Initiates Revolution Medicines at Outperform With $90 Price Target	MT
17/10/25	Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment	DJ
11/09/25	Wedbush Raises Price Target on Revolution Medicines to $77 From $73, Keeps Outperform Rating	MT
05/09/25	Truist Initiates Revolution Medicines at Buy With $99 Price Target	MT
18/08/25	LifeSci Capital Initiates Revolution Medicines at Outperform With $80 Price Target	MT
15/08/25	Wells Fargo Initiates Revolution Medicines at Overweight With $67 Price Target	MT
24/06/25	Wedbush Lifts Price Target on Revolution Medicines to $73 From $67, Keeps Outperform Rating	MT
08/01/25	UBS Adjusts Price Target on Revolution Medicines to $71 From $65, Keeps Buy Rating	MT
06/12/24	Wedbush Cuts Price Target on Revolution Medicines to $67 From $70, Keeps Outperform Rating	MT
02/12/24	Stifel Raises Price Target on Revolution Medicines to $80 From $70, Maintains Buy Rating	MT
18/07/24	Barclays Adjusts Price Target on Revolution Medicines to $54 From $52, Maintains Overweight Rating	MT
17/07/24	UBS Adjusts Price Target on Revolution Medicines to $65 From $40, Maintains Buy Rating	MT
16/07/24	Needham Adjusts Revolution Medicines Price Target to $62 From $46, Maintains Buy Rating	MT
16/07/24	HC Wainwright Raises Price Target on Revolution Medicines to $56 From $44, Maintains Buy Rating	MT
16/07/24	Oppenheimer Adjusts Revolution Medicines Price Target to $55 From $45, Maintains Outperform Rating	MT
15/07/24	Wedbush Raises Price Target on Revolution Medicines to $59 From $46, Maintains Outperform Rating	MT
12/07/24	Barclays Initiates Revolution Medicines at Overweight With $52 Price Target	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Analyst Reco. Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Biotechnology & Medical Research

Analyst Reco.

Filters